近日，中国科学家在抗癌研究领域取得重大突破，发现了一种具有潜力的新型抗癌‘利器’——一种能够精准识别并摧毁癌细胞的小分子化合物。该研究成果由中科院上海药物研究所联合多家科研机构共同完成，并已发表于国际权威期刊《自然·医学》。研究团队通过高通量筛选技术，从数万种化合物中筛选出一种代号为‘SMC-2024’的分子，它能特异性结合癌细胞表面过度表达的某种受体蛋白，从而激活细胞内部的凋亡通路，诱导癌细胞程序性死亡，同时对正常细胞几乎无毒副作用。在动物实验中，接受该化合物治疗的小鼠肿瘤体积显著缩小，生存期明显延长。专家表示，这一发现为开发新一代靶向抗癌药物提供了重要基础，有望在未来几年进入临床试验阶段。相较于传统化疗，这种新型疗法更具精准性和安全性，可能为多种难治性癌症（如胰腺癌、三阴性乳腺癌等）患者带来新希望。目前，研究团队正与制药企业合作，加速推进药物研发进程。
Recently, Chinese scientists have made a significant breakthrough in cancer research by identifying a promising new ‘weapon’ against cancer—a small-molecule compound capable of precisely targeting and eliminating cancer cells. This discovery was led by the Shanghai Institute of Materia Medica, Chinese Academy of Sciences, in collaboration with multiple research institutions, and has been published in the prestigious international journal Nature Medicine.Using high-throughput screening technology, the research team identified a compound designated ‘SMC-2024’ from tens of thousands of candidates. This molecule specifically binds to a receptor protein that is overexpressed on the surface of cancer cells, triggering an internal apoptotic pathway that induces programmed cell death—while showing minimal toxicity to healthy cells. In animal trials, mice treated with SMC-2024 exhibited significantly reduced tumor volumes and markedly extended survival times.Experts note that this finding lays a crucial foundation for developing next-generation targeted cancer therapies and could enter clinical trials within the next few years. Compared to conventional chemotherapy, this novel approach offers greater precision and safety, potentially offering new hope for patients with hard-to-treat cancers such as pancreatic cancer and triple-negative breast cancer. The research team is currently partnering with pharmaceutical companies to accelerate drug development.
原创文章，作者：admin，如若转载，请注明出处：https://ktez.cn/3386.html